Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergic Contact Dermatitis Clear all
Not yet recruiting Not applicable Interventional

Use of Silk Fibroin Dressings in Primary Total Hip Arthroplasty

NCT07868900
View directory record Official record
Conditions
Allergic Contact Dermatitis (ACD)
Interventions
Dermabond PRINEO, Silk fibroin
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cutaneous and Systemic Reactions to Metal Implants

NCT02483728
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
Patch Test
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Mineola, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents

NCT01797562
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Panels 1.3, 2.2 and 3.2 experimental allergens
Diagnostic Test
Lead sponsor
Allerderm
Industry
Eligibility
6 Years to 17 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
San Diego, California • Aurora, Colorado • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Aquacel Hypersensitivity Dressing in TJAs

NCT06011629
View directory record Official record
Conditions
Contact Allergic Dermatitis, Adverse Skin Reaction
Interventions
Aquacel dressing
Device
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Clinical Evaluation of T.R.U.E. TEST in Children and Adolescents

NCT00795951
View directory record Official record
Conditions
Dermatitis, Contact
Interventions
T.R.U.E. Test
Biological
Lead sponsor
Allerderm
Industry
Eligibility
6 Years to 18 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects

NCT03945760
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Wright State Physicians
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Test for Photo Allergy Reaction of Sunscreens

NCT02872220
View directory record Official record
Conditions
Photoallergy
Interventions
SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pinellas Park, Florida
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 4 Interventional Results available

Bioequivalence of Ethylenediamine Dihydrochloride Study

NCT01798589
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Ethylenediamine dihydrochloride allergen patch
Drug
Lead sponsor
Allerderm
Industry
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 26, 2026, 5:46 PM EDT
Withdrawn Not applicable Interventional

Intranasal Neurostimulation for the Treatment of Neurosensory Abnormalities in CL Wearers (INTAC)

NCT04240587
View directory record Official record
Conditions
Contact Allergy, Neuropathic Pain
Interventions
TrueTear™ intranasal neurostimulator (ITN)
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 26, 2026, 5:46 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

NCT05535738
View directory record Official record
Conditions
Skin Inflammation, Allergic Contact Dermatitis
Interventions
Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab, Adalimumab, Ustekinumab, Guselkumab, Canakinumab, Sarilumab, Triamcinolone Acetonide, Betamethasone Valerate, Fluticasone Propionate, Microneedle, Suction blistering, Skin punch biopsy
Drug · Other · Device + 1 more
Lead sponsor
Wei-Che Ko
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Not listed Not applicable Interventional

Patient Experience and Quality of Patch Testing on the Legs vs Back

NCT06191627
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Patch testing
Diagnostic Test
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2024 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Study of the Intradermal Injection of rHuPH20 or Placebo in Participants With Nickel Allergic Contact Dermatitis

NCT00928447
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
rHuPH20, Placebo
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Michigan City, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis

NCT03680131
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
EB01 Cream Placebo, EB01 Cream 0.2%, EB01 Cream 1.0%, EB01 Cream 2.0%
Drug
Lead sponsor
Edesa Biotech Inc.
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
14
States / cities
Long Beach, California • Washington D.C., District of Columbia • Delray Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Allergy Skin Patch Artificial Intelligence (AI)

NCT05339750
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
AI-based smartphone application, Allergen patch
Device · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 26, 2026, 5:46 PM EDT
Active, not recruiting Phase 4 Interventional Results available

The Effects of Dupilumab on Allergic Contact Dermatitis

NCT03935971
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction

NCT07217613
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
silk fibroin-based incision dressing, cyanoacrylate-based closure system
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
14 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Not yet recruiting Not applicable Interventional

Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery

NCT07573202
View directory record Official record
Conditions
Hypersensitivity Reactions, Allergic Contact Dermatitis
Interventions
Silk fibroin (SYLKE), 2-octyl cyanoacrylate mesh (Dermabond PRINEO)
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Study of Apremilast in Atopic or Contact Dermatitis

NCT00931242
View directory record Official record
Conditions
Atopic Dermatitis, Allergic Contact Dermatitis
Interventions
Apremilast
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2010 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

CP-481,715 Nickel Allergy Study.

NCT00141180
View directory record Official record
Conditions
Dermatitis, Allergic Contact
Interventions
CP-481,715
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
4
States / cities
Ann Arbor, Michigan • New York, New York • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2006 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 4 Interventional

Study of the Safety and Efficacy of Tacrolimus Ointment in Treating Chronic Allergic Contact Dermatitis

NCT00667056
View directory record Official record
Conditions
Dermatitis
Interventions
tacrolimus ointment, placebo ointment
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
17 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
10
States / cities
Washington D.C., District of Columbia • Kansas City, Kansas • Shawnee, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 2 Interventional

Clinical Evaluation of Bacitracin

NCT00132600
View directory record Official record
Conditions
Allergic Contact Dermatitis
Interventions
bacitracin (allergen)
Drug
Lead sponsor
Mekos Laboratories AS
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 19, 2005 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Find Out if Cream V61-044 Used to Treat Fungal Infections Causes an Allergic Skin Reaction to Sunlight in Healthy Participants

NCT04532164
View directory record Official record
Conditions
Dermatitis, Photoallergic
Interventions
Butenafine HCl 1% (BAY1896425) - Induction Phase, Butenafine HCl 1% (BAY1896425) - Challenge Phase
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Fairfield, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 26, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of Tetrix Cream in the Healing of Injured Skin in Subjects With Contact Dermatitis

NCT00643214
View directory record Official record
Conditions
Healthy
Interventions
Tetrix
Device
Lead sponsor
Coria Laboratories, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 22, 2008 · Synced Oct 26, 2026, 5:46 PM EDT
Enrolling by invitation Not applicable Interventional

Rate of Allergic Contact Dermatitis and Cosmetic Outcomes

NCT06957444
View directory record Official record
Conditions
Allergic Contact Dermatitis, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions
Sylke Adhesive Dressing, Exofin Skin Glue, Suture Strip Plus
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 5:46 PM EDT